文献速递冠心病

新型高敏心肌肌钙蛋白 T 检测早期排除心肌梗死研究

Early Rule Out of Myocardial Infarction With a Novel High-Sensitivity Cardiac Troponin T Assay.
PubMed 文献 · JAMA Cardiol · 2026-01-01

该前瞻性多中心队列研究纳入苏格兰衍生队列与欧洲五国验证队列的可能非 ST 段抬高型心肌梗死成人患者,评估第六代高敏心肌肌钙蛋白 T(hs-cTnT)检测在就诊时早期排除心肌梗死或心源性死亡的表现。结果显示,就诊时第六代 hs-cTnT 低于 13 ng/L 可识别低风险患者,衍生队列阴性预测值为 99.9%,验证队列为 99.0%。与第五代检测相比,第六代检测在早期排除路径中识别的低风险患者比例更高。

要点

  • 第六代 hs-cTnT 低于 13 ng/L 可用于就诊时早期排除心肌梗死或心源性死亡。
  • 衍生队列该阈值阴性预测值 99.9%,敏感性 99.4%。
  • 第六代检测识别低风险患者比例高于第五代检测。

核心结论

  • 与第五代 hs-cTnT 检测相比,基于临床性能设定风险分层阈值的第六代检测可在就诊时识别更多心肌梗死或心源性死亡低风险患者。

研究设计与样本

  • 前瞻性多中心队列研究,衍生队列 2022 至 2025 年于苏格兰急诊科招募。
  • 验证队列 2014 至 2019 年于捷克、意大利、波兰、西班牙和瑞士急诊科招募。
  • 纳入可能非 ST 段抬高型心肌梗死的成人患者,衍生队列共 987 例。
  • 研究数据分析时间为 2025 年 5 月至 10 月。
  • 就诊时及系列样本采用第五代和新型第六代 hs-cTnT 检测心肌肌钙蛋白浓度。

主要发现

  • 衍生队列 987 例患者中 82 例(8.3%)达到主要结局,即 30 天 1 型、4b 型或 4c 型心肌梗死或心源性死亡。
  • 衍生队列就诊时 601 例(61%)第六代 hs-cTnT 浓度低于 13 ng/L。
  • 衍生队列第六代 hs-cTnT 低于 13 ng/L 的阴性预测值为 99.9%,敏感性为 99.4%。
  • 早期排除路径中第六代检测识别低风险患者 376 例(41.0%),高于第五代检测的 160 例(17.4%)。
  • 验证队列 1721 例中 782 例(45.4%)第六代 hs-cTnT 低于 13 ng/L,阴性预测值为 99.0%,敏感性为 97.5%。

关键数值与推荐

  • 主要结局定义为 30 天 1 型、4b 型或 4c 型心肌梗死或心源性死亡。
  • 低风险阈值定义为就诊时阴性预测值不低于 99.5% 且敏感性不低于 99% 的最高浓度。
  • 第六代 hs-cTnT 低风险分层阈值为就诊时低于 13 ng/L。
  • 衍生队列第六代 hs-cTnT 低于 13 ng/L 的 95% 可信区间为 99.7% 至 100%,敏感性 95% 可信区间为 97.7% 至 100%。
  • 验证队列第六代 hs-cTnT 低于 13 ng/L 的阴性预测值 95% 可信区间为 98.3% 至 99.6%,敏感性 95% 可信区间为 95.8% 至 99.0%。

临床怎么用

  • 急诊科可使用第六代 hs-cTnT 低于 13 ng/L 作为就诊时早期排除心肌梗死或心源性死亡的阈值。
  • 与第五代检测相比,第六代检测可提高就诊时即被识别为低风险的患者比例。
  • 实施该早期排除路径对临床实践的影响仍需前瞻性研究评估。

局限性

  • 研究未提供第六代检测在非欧洲人群中的表现数据。
  • 研究未报告早期排除路径实施后的临床结局或资源使用变化。
  • 研究未提供第六代检测的系列采样诊断性能数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: In the emergency department, patients at low risk of myocardial infarction can be identified at presentation using a single cardiac troponin measurement with high-sensitivity assay. OBJECTIVES: To define a threshold to identify patients at low risk of myocardial infarction for the sixth-generation high-sensitivity cardiac troponin T (hs-cTnT) assay and to evaluate the impact of applying this in an early rule-out pathway. DESIGN, SETTING, AND PARTICIPANTS: This was a prospective multicenter cohort study conducted from 2022 to 2025 (derivation cohort) and 2014 to 2019 (validation cohort). The setting included emergency departments at hospitals in Scotland (derivation cohort) and Czechia, Italy, Poland, Spain, and Switzerland (validation cohort). Participants included adults with possible non-ST-segment elevation myocardial infarction (both cohorts). Study data were analyzed from May to October 2025. EXPOSURES: Cardiac troponin concentration measured at presentation and on serial samples using fifth-generation and novel sixth-generation hs-cTnT assays. MAIN OUTCOMES AND MEASURES: Outcomes included the highest threshold at presentation with negative predictive value (NPV) greater than or equal to 99.5% and sensitivity greater than or equal to 99% for an adjudicated primary outcome of type 1, 4b, or 4c myocardial infarction or cardiac death at 30 days. Performance of an early rule-out pathway with the sixth-generation assay. RESULTS: In total, 987 patients (median [IQR] age, 59 [50-70] years; 611 male [62%]) were recruited, with 82 (8.3%) meeting the primary outcome. At presentation, 601 patients (61%) had a cardiac troponin T concentration less than 13 ng/L using the sixth-generation hs-cTnT assay, with an NPV of 99.9% (95% credible interval [CrI], 99.7%-100%) and sensitivity of 99.4% (95% CrI, 97.7%-100%). More patients were identified as low risk at presentation in the early rule-out pathway when using the sixth-generation assay compared with fifth-generation assay (376 [41.0%] vs 160 [17.4%]; P < .001). In the external validation cohort, 782 of 1721 patients (45.4%) had a sixth-generation hs-cTnT measurement less than 13 ng/L at presentation with an NPV of 99.0% (95% Cr, 98.3%-99.6%) and sensitivity of 97.5% (95% Cr, 95.8%-99.0%), compared with 118 (6.9%) below the low risk-stratification threshold of the fifth-generation hs-cTnT assay (P < .001). CONCLUSIONS AND RELEVANCE: Results of this cohort study suggest that compared with the fifth-generation hs-cTnT assay, use of the sixth-generation assay with a risk-stratification threshold based on clinical performance could double identification of patients at low risk of myocardial infarction or cardiac death at presentation. Prospective studies are required to evaluate the impact of implementation on practice.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Thurston, Tew, Lopez-Ayala, et al. Early Rule Out of Myocardial Infarction With a Novel High-Sensitivity Cardiac Troponin T Assay. JAMA Cardiol. 2026. PMID: 42018311. doi:10.1001/jamacardio.2026.0477

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。